Phase 2 data reported nausea (~42%), vomiting (~20%), and diarrhoea (~18%) in the highest dose cohort, consistent with the GLP-1 class
Product Specifications Product Retatrutide 10mg Peptide Class Triple Agonist (GLP-1/GIP/Glucagon Receptor) Appearance Lyophilised, Good Purity 99.84% (Full QC Panel HPLC) Net Peptide Content 10.66 mg per vial Lot Number 126-01-SM COA Number COA-2026-DRUUMA Testing Lab ILS Laboratories, San Diego (ISO/IEC 17025 Accredited) Fentanyl Screen Not Detected (Pass) Sterility (PCR) No Growth (Pass) Heavy Metals Arsenic, Cadmium, Chromium, Mercury, Lead All Not Detected (Pass) Storage Lyophilised: -20C
Microdosing semaglutide refers to taking doses of semaglutide that are lower than the doses typically prescribed or studied for weight loss or diabetes management
Moreover, mice given either fusion consistently demonstrated an increase in the plasma concentrations of insulin following the glucose challenge (Fig
For many Austin patients, the success of GLP-1 medications (like Ozempic or Wegovy) comes with an unexpected aesthetic "tax." While the scale is moving in the right direction, many are noticing a sudden increase in hair shedding and a loss of muscle definitionoften referred to as "GLP-1 Shedding" or muscle wasting
Implications GLP-1RAs represent a novel, multifaceted therapeutic option in PsD, targeting both metabolic and inflammatory components
